0001140361-14-014134.txt : 20140325 0001140361-14-014134.hdr.sgml : 20140325 20140325181027 ACCESSION NUMBER: 0001140361-14-014134 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140321 FILED AS OF DATE: 20140325 DATE AS OF CHANGE: 20140325 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sanofi CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 14717000 BUSINESS ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 54 RUE LA BOETIE CITY: PARIS STATE: I0 ZIP: 75008 FORMER NAME: FORMER CONFORMED NAME: SANOFI-AVENTIS DATE OF NAME CHANGE: 20040826 FORMER NAME: FORMER CONFORMED NAME: SANOFI SYNTHELABO SA DATE OF NAME CHANGE: 20010104 4 1 doc1.xml FORM 4 X0306 4 2014-03-21 0 0000872589 REGENERON PHARMACEUTICALS INC REGN 0001121404 Sanofi 54 RUE LA BOETIE PARIS I0 75008 FRANCE 0 0 1 0 Common Stock 2014-03-21 4 P 0 5024 313.1237 A 18183274 I See note Common Stock 2014-03-21 4 P 0 10934 314.2130 A 18194208 I See note Common Stock 2014-03-21 4 P 0 14463 315.0737 A 18208671 I See note Common Stock 2014-03-21 4 P 0 5700 316.1587 A 18214371 I See note Common Stock 2014-03-21 4 P 0 23644 317.2291 A 18238015 I See note Common Stock 2014-03-21 4 P 0 26229 318.3630 A 18264244 I See note Common Stock 2014-03-21 4 P 0 37436 319.1846 A 18301680 I See note Common Stock 2014-03-21 4 P 0 23411 320.0872 A 18325091 I See note Common Stock 2014-03-21 4 P 0 16036 321.2298 A 18341127 I See note Common Stock 2014-03-21 4 P 0 21101 322.2800 A 18362228 I See note Common Stock 2014-03-21 4 P 0 27688 323.3238 A 18389916 I See note Common Stock 2014-03-21 4 P 0 31754 324.0934 A 18421670 I See note Common Stock 2014-03-21 4 P 0 25116 325.1870 A 18446786 I See note Common Stock 2014-03-21 4 P 0 13905 326.1081 A 18460691 I See note Common Stock 2014-03-21 4 P 0 8918 327.0443 A 18469609 I See note Common Stock 2014-03-21 4 P 0 7476 328.2175 A 18477085 I See note Common Stock 2014-03-21 4 P 0 1749 329.1682 A 18478834 I See note Common Stock 2014-03-21 4 P 0 506 330.3839 A 18479340 I See note Common Stock 2014-03-21 4 P 0 2110 331.4914 A 18481450 I See note Common Stock 2014-03-21 4 P 0 1915 332.7833 A 18483365 I See note The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN"). Purchase prices range from $312.50 to $313.49 per share, inclusive. Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 15,683,813 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuers Board of Directors. Purchase prices range from $313.59 to $314.58 per share, inclusive. Purchase prices range from $314.59 to $315.55 per share, inclusive. Purchase prices range from $315.69 to $316.65 per share, inclusive. Purchase prices range from $316.71 to $317.70 per share, inclusive. Purchase prices range from $317.72 to $318.71 per share, inclusive. Purchase prices range from $318.72 to $319.71 per share, inclusive. Purchase prices range from $319.72 to $320.71 per share, inclusive. Purchase prices range from $320.75 to $321.74 per share, inclusive. Purchase prices range from $321.75 to $322.70 per share, inclusive. Purchase prices range from $322.75 to $323.74 per share, inclusive. Purchase prices range from $323.75 to $324.73 per share, inclusive. Purchase prices range from $324.75 to $325.73 per share, inclusive. Purchase prices range from $325.75 to $326.68 per share, inclusive. Purchase prices range from $326.78 to $327.60 per share, inclusive. Purchase prices range from $327.79 to $328.77 per share, inclusive. Purchase prices range from $328.82 to $329.61 per share, inclusive. Purchase prices range from $330.00 to $330.76 per share, inclusive. Purchase prices range from $331.05 to $331.99 per share, inclusive. Purchase prices range from $332.39 to $333.00 per share, inclusive. Due to technical limitation of the number of transactions reported, this report is 1 of 2. /s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law 2014-03-25